|
Oncogenes and Tumor Suppressors
Citations 151-160 of 795 total displayed.
|
Past content
(since May 2000):
|
Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis
- Nicolaus Kröger, Anita Badbaran, Ernst Holler, Joachim Hahn, Guido Kobbe, Martin Bornhäuser, Andreas Reiter, Tatjana Zabelina, Axel R. Zander, and Boris Fehse
Blood 2007; 109: 1316-1321.
[Abstract]
[Full text]
[PDF]
Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?
- Krzysztof Mrózek, Guido Marcucci, Peter Paschka, Susan P. Whitman, and Clara D. Bloomfield
Blood 2007; 109: 431-448.
[Abstract]
[Full text]
[PDF]
Dasatinib (BMS-354825) is active in Philadelphia chromosome–positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure
- Alfonso Quintas-Cardama, Hagop Kantarjian, Dan Jones, Claude Nicaise, Susan O'Brien, Francis Giles, Moshe Talpaz, and Jorge Cortes
Blood 2007; 109: 497-499.
[Abstract]
[Full text]
[PDF]
KLF4 suppresses transformation of pre-B cells by ABL oncogenes
- Michael G. Kharas, Isharat Yusuf, Vanessa M. Scarfone, Vincent W. Yang, Julia A. Segre, Claudia S. Huettner, and David A. Fruman
Blood 2007; 109: 747-755.
[Abstract]
[Full text]
[PDF]
Rce1 deficiency accelerates the development of K-RAS–induced myeloproliferative disease
- Annika M. Wahlstrom, Briony A. Cutts, Christin Karlsson, Karin M. E. Andersson, Meng Liu, Anna-Karin M. Sjogren, Birgitta Swolin, Stephen G. Young, and Martin O. Bergo
Blood 2007; 109: 763-768.
[Abstract]
[Full text]
[PDF]
Aberrant transcriptional regulation of the MLL fusion partner EEN by AML1-ETO and its implication in leukemogenesis
- Li-Heng Ma, Han Liu, Hui Xiong, Bing Chen, Xiao-Wei Zhang, Yue-Ying Wang, Huang-Ying Le, Qiu-Hua Huang, Qing-Hua Zhang, Bo-Liang Li, Zhu Chen, and Sai-Juan Chen
Blood 2007; 109: 769-777.
[Abstract]
[Full text]
[PDF]
SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl
- Jing Chen, Wen-Mei Yu, Hanako Daino, Hal E. Broxmeyer, Brian J. Druker, and Cheng-Kui Qu
Blood 2007; 109: 778-785.
[Abstract]
[Full text]
[PDF]
Regulation of the Arf tumor suppressor in Eµ-Myc transgenic mice: longitudinal study of Myc-induced lymphomagenesis
- David Bertwistle and Charles J. Sherr
Blood 2007; 109: 792-794.
[Abstract]
[Full text]
[PDF]
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
- Philippe Rousselot, Francoise Huguet, Delphine Rea, Laurence Legros, Jean Michel Cayuela, Odile Maarek, Odile Blanchet, Gerald Marit, Eliane Gluckman, Josy Reiffers, Martine Gardembas, and François-Xavier Mahon, The Intergroupe Français des Leucémies Myéloïdes Chronique (FI
 LMC)
Blood 2007; 109: 58-60.
[Abstract]
[Full text]
[PDF]
Durable responses to imatinib in patients with PDGFRB fusion gene–positive and BCR-ABL–negative chronic myeloproliferative disorders
- Marianna David, Nicholas C. P. Cross, Sonja Burgstaller, Andrew Chase, Claire Curtis, Raymond Dang, Martine Gardembas, John M. Goldman, Francis Grand, George Hughes, Francoise Huguet, Louise Lavender, Grant A. McArthur, Francois X. Mahon, Giorgio Massimini, Junia Melo, Philippe Rousselot, Robin J. Russell-Jones, John F. Seymour, Graeme Smith, Alastair Stark, Katherine Waghorn, Zariana Nikolova, and Jane F. Apperley
Blood 2007; 109: 61-64.
[Abstract]
[Full text]
[PDF]
|
|
